Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 7/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | GMNN | O75496 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749621 | 0.78 | TSHR (0.45) | TSHRSLC22A6MMP1MMP2MMP3 | |
| SCHEMBL15864631 | 0.76 | TSHR (0.47) | TDP1TSHRSLC22A6CYP1A2LMNA | |
| SCHEMBL1289946 | 0.75 | TDP1 (0.45) | TDP1TSHRSLC22A6MMP1MMP2 | |
| SCHEMBL3472423 | 0.75 | TDP1 (0.45) | TDP1MMP1MMP2MMP3MMP9 | |
| SCHEMBL1864892 | 0.74 | LMNA (0.42) | TSHRSLC22A6MMP1MMP2MMP3 | |
| Adipic Acid SCHEMBL8022842 | 0.74 | TDP1 (0.74) | TDP1TSHRSLC22A6LMNAMEN1 | |
| SCHEMBL9616895 | 0.73 | TDP1 (0.52) | TDP1TSHRSLC22A6MMP1MMP2 | |
| SCHEMBL8127304 | 0.73 | TDP1 (0.52) | TDP1TSHRSLC22A6MMP1MMP2 | |
| SCHEMBL68486 | 0.72 | LMNA (0.45) | TSHRSLC22A6MMP1MMP2MMP3 | |
| Octanedioate SCHEMBL21048736 | 0.72 | TDP1 (0.70) | TDP1TSHRSLC22A6LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177548-A1 | Methods and Compositions for Treating Melanoma | WISTAR INST (US) | 2022-06-09 | — | — | US | disclosed |
| US-11208468-B2 | Methods and compositions for treating melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190276517-A1 | Methods and Compositions for Treating Melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2019-09-12 | — | — | US | disclosed |
| US-7811993-B2 | Methods and compositions for treating melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100203109-A1 | Methods and Compositions for Treating Melanoma | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2010-08-12 | — | — | US | disclosed |
| US-7189691-B2 | Methods and compositions for treating leukemia | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2007002811-A2 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050222012-A1 | Methods and compositions for treating leukemia | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2005-10-06 | — | — | US | disclosed |
| US-20030064918-A1 | Compounds and uses thereof in treating bone disorders | AUCKLAND UNISERVICES LIMITED, NEW ZEALAND CORPORATION | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064918-A1 | Compounds and uses thereof in treating bone disorders | BMP2, SOST, BMP6 | TDP1 4369/4885TSHR 3087/4885SLC22A6 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.